Shots:

• Dermira to receive $30M upfront. Almira to get exclusive option to license rights for Dermira’s lebrikizumab to develop in dermatology & commercialize it in all indications in EU- with 45 days to exercise the option on basis of its P-IIb results
• If Almirall exercises its option- Dermira will receive $50M as option exercise fee- $30M milestones on the onset of P-III trial- $85M as regulatory milestone and on first sale in EU- and threshold milestones & royalties on net sales of lebrikizumab in EU
• Lebrikizumab is a mAb- bind to IL-13- involved in prevention of the formation of IL-13Rα1/IL-4Rα heterodimer complex and is evaluated in P-IIb study in 280 patients with moderate-to-severe atopic dermatitis aged >18yrs.

Ref: Globe Newswire | Image: Pharmaphorum